<DOC>
	<DOCNO>NCT00530621</DOCNO>
	<brief_summary>The purpose study determine combination enzastaurin pemetrexed extend survival time without progression disease patient advance metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Study Enzastaurin Versus Placebo With Pemetrexed Patients With Advanced Metastatic Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Laboratory confirm diagnosis NSCLC locally advance metastatic disease cure . Patients must disease progress 1 prior systemic cytotoxic chemotherapy regimen advance disease . At least 1 measurable lesion . Must stop previous systemic therapy cancer least 2 week prior enrollment . Must able follow study guideline able show appointment . Treatment within last 30 day drug receive regulatory approval indication time study entry . Previous treatment enzastaurin pemetrexed . Concurrent administration antitumor therapy . Inability swallow tablet Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>